Key result
Treatment with carbamazepine resulted in complete abolition of recurrent laryngospasm and alleviated symptoms associated with myotonia and muscle stiffness in 3 patients with SCN4A mutations.
Why the study?
Does carbamazepine improve recurrent laryngospasm in infants with SCN4A mutations?
Case Report (n=3)
Does carbamazepine improve recurrent laryngospasm in infants with SCN4A mutations?
SCN4A mutations are a rare but treatable cause of recurrent infantile laryngospasm that responds completely to carbamazepine.
Answers are grounded in this paper and cite their sources.
May warrant carbamazepine consideration in SCN4A laryngospasm; hypothesis-generating and requires controlled validation.
Laryngospasm is a rare but potentially life-threatening occurrence in infants and usually has infective, allergic, metabolic, or anatomic causes. Underlying genetic conditions are rarely considered. Mutations in SCN4A encoding the voltage-gated sodium channel NaV1.4 have been implicated in a wide spectrum of neuromuscular disorders with variable onset, ranging from a rare form of congenital myasthenic syndrome to both hypokalemic and hyperkalemic forms of periodic paralysis and paramyotonia congenita. Here we report on 3 unrelated patients without family history presenting with recurrent, life-threatening episodes of laryngospasm from the first months of life. Clinical features more typically associated with SCN4A-related disorders such as generalized muscle hypertrophy with clinical or electrical myotonia evolved later in life. All patients were found to be heterozygous for the same SCN4A mutation, c.3917G>A; p.Gly1306Glu. Treatment with carbamazepine resulted in complete abolition of recurrent laryngospasm and alleviated symptoms associated with myotonia and muscle stiffness. We conclude that SCN4A mutations ought to be considered in the differential diagnosis of recurrent infantile laryngospasm because timely institution of treatment can be life-saving.
No takes yet. Share an insight, caveat, or question.
Singh et al. (2014) conducted a case report in Recurrent life-threatening laryngospasm (n=3). Carbamazepine was evaluated on Abolition of recurrent laryngospasm and alleviation of symptoms. Treatment with carbamazepine resulted in complete abolition of recurrent laryngospasm and alleviated symptoms associated with myotonia and muscle stiffness in 3 patients with SCN4A mutations.
Synapse has enriched 10 related papers. Consider them for comparative context: